主页 文献库文献详情
PMID: 25143196 已发表 · ppublish 英语

Protective effects of calycosin against CCl4-induced liver injury with activation of FXR and STAT3 in mice.

Pharmaceutical research ·第 32 卷 ·第 2 期 ·2015-10-26

Chen Xinli, Meng Qiang, Wang Changyuan, Liu Qi, Sun Huijun, Huo Xiaokui, Sun Pengyuan, Yang Xiaobo, Peng Jinyong, Liu Kexin

摘要

Investigating the hepatoprotective effect of calycosin against acute liver injury in association with FXR activation and STAT3 phosphorylation.,The acute liver injury model was established by intraperitoneal injection of CCl4 in C57BL/6 mice. Serum alanine aminotransferase, aspartate aminotransferase, HE staining and TUNEL assay were used to identify the amelioration of the liver histopathological changes and hepatocytes apoptosis after calycosin treatment. ELISA kit and 5-bromo-2-deoxyuridine immunohistochemistry were used to measure the liver bile acid concentration and hepatocyte mitotic rate in vivo. The relation between calycosin and activation of FXR and STAT3 was comfirmed using the Luciferase assay, Molecular docking, Real-time PCR and Western Blot in vitro.,The liver histopathological changes, hepatocytes apoptosis, liver bile acid overload and hepatocyte mitosis showed significant changes after calycosin treatment. Calycosin promoted the expression of FXR target genes such as FoxM1B and SHP but the effect was reversed by FXR suppressor guggulsterone. Molecular docking results indicated that calycosin could be embedded into the binding pocket of FXR, thereby increasing the expressions of STAT3 tyrosine phosphorylation and its target genes, Bcl-xl and SOCS3.,Calycosin plays a critical role in hepatoprotection against liver injury in association with FXR activation and STAT3 phosphorylation.

文献信息
期刊
Pharmaceutical research
期刊简称
Pharm Res
发表日期
2015-10-26
收录日期
2015-01-21
更新日期
2016-11-25
语言
英语
国家/地区
United States
NLM ID
8406521
分析服务
分析服务

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]